Surrogate markers in antiangiogenesis clinical trials
نویسندگان
چکیده
منابع مشابه
Biomarkers and surrogate endpoints in clinical trials.
One of the most important considerations in designing clinical trials is the choice of outcome measures. These outcome measures could be clinically meaningful endpoints that are direct measures of how patients feel, function, and survive. Alternatively, indirect measures, such as biomarkers that include physical signs of disease, laboratory measures, and radiological tests, often are considered...
متن کاملClinical Trials of Antiangiogenesis Therapy on Gastric Cancer
Both malignant tumor growth and metastasis are dependent upon angiogenesis, a process of new blood vessel formation. Inhibition of this process by specific inhibitors might be able to control tumor growth and metastasis. Therefore, antiangiogenesis thereapy is considered a promising strategy and being studied worldwide. A wide variety of angiogenesis inhibitors have been identified and some of ...
متن کاملDefining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
BACKGROUND Clinical trials in severe falciparum malaria require a large sample size to detect clinically meaningful differences in mortality. This means few interventions can be evaluated at any time. Using a validated surrogate endpoint for mortality would provide a useful alternative allowing a smaller sample size. Here we evaluate changes in coma score and plasma lactate as surrogate endpoin...
متن کاملSurrogate end points in clinical trials: are we being misled?
Phase 3 clinical trials, which evaluate the effect that new interventions have on the clinical outcomes of particular relevance to the patient (such as death, loss of vision, or other major symptomatic event), often require many participants to be followed for a long time.There has recently been great interest in using surrogate end points, such as tumor shrinkage or changes in cholesterol leve...
متن کاملTitle Evaluation of Surrogate Endpoints in Clinical Trials
May 15, 2015 Type Package Title Evaluation of Surrogate Endpoints in Clinical Trials Version 0.1-6 Date 2015-05-14 Author Wim Van der Elst, Ariel Alonso & Geert Molenberghs Maintainer Wim Van der Elst Description In a clinical trial, it frequently occurs that the most credible outcome to evaluate the effectiveness of a new therapy (the true endpoint) is difficult to m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 2003
ISSN: 0007-0920,1532-1827
DOI: 10.1038/sj.bjc.6601035